Literature DB >> 22005098

Comparative analysis of patients with acute coronary and cerebrovascular syndromes from the national French hospitalization health care system database.

Yannick Béjot1, Eric Benzenine, Luc Lorgis, Marianne Zeller, Hervé Aubé, Maurice Giroud, Yves Cottin, Catherine Quantin.   

Abstract

BACKGROUND: Nationwide evaluations of the epidemiology of acute coronary syndrome (ACS) or cerebrovascular syndrome (CVS) are scarce. We aimed to analyze nationwide French data on patients referred to hospital for either ACS or CVS.
METHODS: Using the French national hospital discharge diagnosis records, all patients hospitalized between 2005 and 2008 with a diagnosis of ACS and CVS based on the ICD-10 were identified. We analyzed vascular risk factors and early outcomes in patients with a single hospitalization for ACS or CVS or for both ACV and CVS in a 2-month time window.
RESULTS: 1,187,643 patients were recorded. Among these, 638,061 (53.7%) had CVS alone, 525,419 (44.3%) had ACS alone, and 24,163 (2%) had both. Patients of the latter group were older, had a higher prevalence of hypertension, diabetes, and atrial fibrillation, a longer length of stay, were less likely to be discharged to home, and had a higher in-hospital risk of death after adjustment for age, sex, and vascular risk factors compared with patients with either CVS alone (OR = 1.71, 95% CI: 1.66-1.77) or ACS alone (OR = 2.95, 95% CI: 2.85-3.05).
CONCLUSION: Patients with both CVS and ACS have a high vascular risk profile and a marked excess risk of early death.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22005098     DOI: 10.1159/000331908

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  1 in total

1.  Differences in Clinical Features in Patients with Acute Coronary Syndrome and Stroke: Japanese Multicenter Registry Results.

Authors:  Ryo Naito; Katsumi Miyauchi; Shuko Nojiri; Norihiro Suzuki; Hiroyuki Daida
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.